...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cancer biology & therapy >Targeted radiation for melanoma: alpha therapy prepares for a beta test.
【24h】

Targeted radiation for melanoma: alpha therapy prepares for a beta test.

机译：黑色素瘤的靶向放射治疗：阿尔法疗法准备进行beta测试。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Patients with locally advanced or metastatic melanoma have few therapeutic options that provide long term survival benefits. The incidence of melanoma has been steadily rising in the United States with estimates of nearly 60,000 cases of melanoma for 2005 with almost 8,000 deaths attributable to this malignancy. The combination of increased patient numbers and a deficiency in effective treatment options has been the impetus for both intensified basic science research and an increase in clinical investigations. Currently clinical trials evaluating the efficacy of chemotherapy, biologic and vaccine based immunotherapy, and radiation therapy are ongoing.Melanoma cells were once thought to be relatively resistant to radiation therapy, however, the routine use of external beam radiation in the palliative setting has demonstrated that local control for metastatic melanoma can be achieved. Although somewhat controversial, these observations have been interpreted to reflect unique radiobiologic characteristicsof melanoma that predict increased efficacy with higher dose per fraction regimens. In the case of ocular melanoma, a more precise role for radiation therapy in local tumor control has been delineated with the use of both ~(125)I plaque brachytherapy and proton therapy. Another pre-clinical radiotherapeutic modality that has recently been developed is the delivery of alpha particle emitting radioisotopes. This strategy of radioimmuotherapyhas the advantage of greater relative biologic effectiveness through the delivery of short range, high linear energy transfer particles (reviewed in ref. 4), a characteristic that may be particularly advantageous for the radiobiology of melanoma.
机译：患有局部晚期或转移性黑色素瘤的患者几乎没有提供长期生存益处的治疗选择。在美国，黑色素瘤的发病率一直在稳步上升，2005年估计有近60,000例黑色素瘤病例，其中约有8,000人死于这种恶性肿瘤。不断增加的患者人数和有效的治疗选择不足的结合，既是加强基础科学研究又是增加临床研究的动力。目前正在进行有关评估化学疗法，基于生物和疫苗的免疫疗法以及放射疗法的疗效的临床试验。黑素瘤细胞曾经被认为对放射疗法具有相对的抵抗力，但是在姑息治疗中常规使用外照射可证明：可以实现转移性黑色素瘤的局部控制。尽管有些争议，但这些观察结果已被解释为反映了黑色素瘤的独特放射生物学特征，这些特征预示着更高的每剂量剂量方案可提高疗效。对于眼部黑色素瘤，已经通过同时使用〜（125）I斑块近距离放射疗法和质子疗法来描述放射疗法在局部肿瘤控制中的更精确作用。最近已经开发出的另一种临床前放射治疗方式是发射α粒子的放射性同位素。这种放射免疫疗法的策略是，通过递送短程，高线性能量转移颗粒（参考文献4进行了综述），具有相对较高的生物学有效性，这对黑色素瘤的放射生物学特别有利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号